BORCS6

BORCS6 (C17orf59) is a subunit of the BORC complex that couples lysosomal positioning and fusion to mTORC1 signaling (PMID:26299971, PMID:34077533). It binds Ragulator and competitively blocks Ragulator's interaction with the Rag GTPases, thereby reducing Rag GTPase localization to the lysosome and impairing amino acid–stimulated recruitment and activation of mTORC1 at the lysosomal surface (PMID:26299971). As a BORC subunit, BORCS6 supports endo-lysosomal trafficking and fusion: loss of BORCS6 causes accumulation of late endosomes and failure of endo-lysosomal degradation during early mouse embryonic development, with the degradation defect attributed to BORC's HOPS-related fusion function rather than to lysosomal positioning (PMID:35726782). BORCS6 is also specifically required for normal lamellar body morphology in lung alveolar epithelial type II cells, where its loss causes lamellar body enlargement (PMID:34077533). Beyond these roles in mTORC1 inhibition and endo-lysosomal maintenance, no further molecular mechanism for BORCS6 has been characterized in the available corpus.

1. 2015 High

   Established the founding molecular function of BORCS6 by showing it is a Ragulator-binding inhibitor of mTORC1, defining a negative regulatory node at the lysosomal surface where amino acid signaling is integrated.

   Evidence Co-immunoprecipitation, in vitro binding assays, lysosomal fractionation, and mTORC1 activity assays in cells

   PMID:26299971

   Open questions at the time

   • Structural basis of the Ragulator–BORCS6 interaction not resolved
   • Physiological conditions that regulate BORCS6 expression or recruitment not defined here
   • Relationship between this mTORC1-inhibitory role and BORC complex assembly not addressed
2. 2021 Medium

   Connected BORCS6 to a tissue-specific organelle phenotype, showing it is selectively required (unlike other BORC subunits) for lamellar body morphology in lung type II cells.

   Evidence CRISPR KO of BORCS6 in A549 cells, proteomics of lamellar bodies from Lrrk2 KO mice, LRRK2 inhibitor treatment, and bronchoalveolar lavage analysis

   PMID:34077533

   Open questions at the time

   • Molecular mechanism linking BORCS6 to lamellar body size not established
   • Why other BORC subunits are dispensable for this phenotype unexplained
   • Direct biochemical interaction between LRRK2 and BORCS6 not demonstrated
3. 2022 Medium

   Defined an in vivo developmental requirement for BORCS6, showing it drives endo-lysosomal degradation needed for normal early embryogenesis via BORC's fusion function.

   Evidence Genetic KO mouse model with embryo phenotyping, endosomal/lysosomal marker immunofluorescence, and lineage analysis

   PMID:35726782

   Open questions at the time

   • Direct evidence distinguishing fusion versus positioning contributions is inferential
   • HOPS-related fusion partners of BORC in this context not identified
   • Whether mTORC1 dysregulation contributes to the embryonic phenotype not tested
4. 2019 Low

   Suggested a physiological setting for BORCS6's mTORC1-inhibitory role, linking its cold-induced expression in T cells to enhanced regulatory T cell induction.

   Evidence qRT-PCR, flow cytometry, in vitro Treg induction assays, humanized mouse model, and human clinical samples

   PMID:31427184

   Open questions at the time

   • Mechanistic link to mTOR/Treg is inferred from prior work rather than directly demonstrated, with no direct mTOR activity measurement reported
   • Causal role of BORCS6 induction in Treg outcomes not established by loss-of-function
   • Single study, single lab
5. 2023 Low

   Raised a potential role for BORCS6 in viral egress, describing SARS-CoV-2 ORF3a recruitment of BORCS6 and ARL8B to drive anterograde lysosomal transport.

   Evidence Review-style mechanistic description of ORF3a interactions

   PMID:37485696

   Open questions at the time

   • Specific experimental methods establishing BORCS6 recruitment not detailed; evidence is indirect
   • Direct ORF3a–BORCS6 binding not shown
   • Functional requirement of BORCS6 for viral egress not tested by perturbation

• How BORCS6's dual roles in mTORC1 inhibition and BORC-dependent lysosomal fusion/positioning are coordinated, and the structural basis of its Ragulator and BORC interactions, remain unresolved.
• No structural model of BORCS6 within Ragulator or BORC
• Mechanism integrating mTORC1 regulation with endo-lysosomal fusion unknown
• Tissue-specific functional differences across cell types not mechanistically explained